Add BrightSurf on Google Email

Novel formulation of an injectable drug to treat joint inflammation acts for ten days

Researchers developed an injectable drug formulation using lipid nanoparticles to sustain the effect of naproxen in treating temporomandibular joint inflammation. The study showed significant reduction in inflammation and absence of side effects, making it a potential treatment option for this condition.

The inflammation connection

Researchers at the Center for Genomic Regulation discovered a novel way to control inflammation by understanding how cells produce IL-1β, a crucial molecule involved in inflammation. By targeting the unfolded protein response and GRASP55 pathways, they identified potential avenues for developing anti-inflammatory drugs.

SourceCenter for Genomic Regulation·JournalDevelopmental Cell·DateApr 1, 2019

Why don't kids use their asthma medicines?

Researchers found that children with asthma often miss their daily medication due to barriers such as forgetfulness and running out of medication. The study suggests that improving communication among patients, families, and pediatric clinicians is crucial to ensure consistent use of daily anti-inflammatory medication.

SourceJohns Hopkins Medicine·JournalJournal of Asthma·DateApr 18, 2018

Certain pain medications linked to increased heart risks

A recent study published in British Journal of Clinical Pharmacology found a significant link between nonsteroidal anti-inflammatory drugs (NSAIDs) and an increased risk of atrial fibrillation. The research highlights the importance of closely monitoring NSAID use for heart health, particularly among high-risk individuals.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateMar 21, 2018

Do pain medications carry different heart risks?

A Taiwanese database study of 55,629 patients with hypertension found no significant difference in cardiovascular risk between cyclooxygenase-2 enzyme selective NSAIDs and nonselective NSAIDs. Most commonly used NSAIDs have similar cardiovascular safety profiles under low-to-moderate daily doses and short-term treatment periods.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateFeb 22, 2018

Flavonoid derivatives targeting NF-kappaB

Researchers synthesized 30 flavanone derivatives to target NF-kappaB, identifying compounds with potent anti-inflammatory and cytotoxic activities against various cancer cell lines. The top-ranked compounds exhibited improved pharmacological profiles through conjugation of two pharmacophores.

SourceBentham Science Publishers·JournalRecent Patents on Inflammation & Allergy Drug Discovery·DateNov 6, 2017

Ethosomes as vesicles for effective transdermal delivery: From bench to clinical implementation

Research highlights ethosomes as a promising nanocarrier system for efficient transdermal drug delivery. The article presents various preclinical and clinical studies showcasing the enhanced absorption and bioavailability of antimicrobials, anti-inflammatory drugs, and CNS acting compounds upon loading into ethosomes.

SourceBentham Science Publishers·JournalCurrent Clinical Pharmacology·DateOct 7, 2016

Ending chronic pain with new drug therapy

Scientists have developed a new treatment strategy that restores a brain region controlling emotions and reduces chronic pain behavior in animal models. The combined drugs target brain circuits and eliminate chronic pain when administered together shortly after an injury.

SourceNorthwestern University·JournalNature Neuroscience·DateDec 21, 2015

Scientists present review of liposomes: A basis for drugs of the future

The review highlights the major achievements in liposome technology, including modern synthesis methods, drug delivery systems, and their use in disease diagnosis. Liposomes are being explored as a potential solution to improve treatment outcomes and reduce side effects for various diseases, including cancer and inflammatory conditions.

SourceMoscow Institute of Physics and Technology·JournalChemical Reviews·DateAug 10, 2015

New smart drug targets and reduces site-specific inflammation

Researchers have developed a dynamic 'smart' drug that targets inflammation in a site-specific manner, reducing side effects. The new anti-inflammatory molecule reduces local inflammation while avoiding normal inflammatory processes, potentially improving treatment outcomes for immunosuppressed patients and those undergoing chemotherapy.

SourceAmerican Associates, Ben-Gurion University of the Negev·JournalThe Journal of Immunology·DateJul 22, 2015

Increasing evidence points to inflammation as source of nervous system manifestations of Lyme disease

A new study published in the American Journal of Pathology shows that inflammation plays a causal role in Lyme disease's neurologic changes, and anti-inflammatory drugs like dexamethasone may prevent these effects. Researchers found that dexamethasone prevented many neuropathologic effects, while meloxicam was generally ineffective.

SourceElsevier Health Sciences·JournalAmerican Journal Of Pathology·DateApr 16, 2015

A second look at glaucoma surgery

A study led by Queen's University professor Robert Campbell revealed that using anti-inflammatory medicines after common eye surgery isn't helpful or necessary. The research found that steroids and nonsteroidal anti-inflammatory drugs do not affect the ability of laser treatment to lower eye pressure.

SourceQueen's University·JournalOphthalmology·DateSep 18, 2014

New discovery solves problem of anti-inflammatory substance

Researchers at Karolinska Institutet have successfully produced a molecule that blocks LTA4 hydrolase from producing LTB4, while maintaining the inactivation of Pro-Gly-Pro. This could lead to new hopes for treating chronic obstructive pulmonary disease (COPD) and various types of inflammatory skin diseases.

SourceKarolinska Institutet·JournalProceedings of the National Academy of Sciences·DateMar 3, 2014

Oxygen levels increase and decrease the effectiveness of anti-inflammatory therapies

Researchers found that oxygen levels alter the effectiveness of anti-inflammatory glucocorticoid drugs in neutrophil lifespans. This discovery may help tailor anti-inflammatory agents to specific diseases, improving treatment outcomes for patients with severe asthma, COPD, and other inflammatory conditions.

SourceFederation of American Societies for Experimental Biology·JournalJournal of Leukocyte Biology·DateDec 2, 2013